Testing effectiveness (Phase 2)UnknownNCT05466175What this trial is testingOlverembatinib in the Treatment of Ph+ ALLWho this might be right forPhiladelphia-Positive ALL Chen Suning 55
Early research (Phase 1)Looking for participantsNCT07282093What this trial is testingPharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentWho this might be right forPharmacokineticOlverembatinib Ascentage Pharma Group Inc. 48
Testing effectiveness (Phase 2)Study completedNCT05594784What this trial is testingOlverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLWho this might be right forPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Institute of Hematology & Blood Diseases Hospital, China 79
Testing effectiveness (Phase 2)Looking for participantsNCT06220487What this trial is testingA Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLWho this might be right forAcute Lymphoblastic LeukemiaPhiladelphia ChromosomePhiladelphia-Positive ALL+2 more Nanfang Hospital, Southern Medical University 67
Not applicableLooking for participantsNCT06481228What this trial is testingEfficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLWho this might be right forPhiladelphia Positive Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, Adult Institute of Hematology & Blood Diseases Hospital, China 82
Large-scale testing (Phase 3)Looking for participantsNCT06640361What this trial is testingOlverembatinib in SDH-deficient GIST.Who this might be right forGIST Ascentage Pharma Group Inc. 40
Testing effectiveness (Phase 2)Study completedNCT04126681What this trial is testingA Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseWho this might be right forChronic Myeloid Leukemia, Chronic Phase Ascentage Pharma Group Inc. 144
Not applicableUnknownNCT05603156What this trial is testingOlverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent PositiveWho this might be right forPh+ ALLBone Marrow TransplantMinimal Residual Disease Institute of Hematology & Blood Diseases Hospital, China 46
Large-scale testing (Phase 3)Looking for participantsNCT06051409What this trial is testingOlverembatinib in Patients With Newly Diagnosed Ph+ALL.Who this might be right forPh+ ALL Ascentage Pharma Group Inc. 350
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06658925What this trial is testingOlverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALLWho this might be right forPh+ Acute Lymphoblastic Leukemia (Ph+ALL)HSCTTyrosine Kinase Inhibitor Institute of Hematology & Blood Diseases Hospital, China 50
Large-scale testing (Phase 3)Looking for participantsNCT07152041What this trial is testingNewly-diagnosed Pediatric Ph-positive B-ALL ProtocolWho this might be right forAcute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)Childhood Leukemia, Acute Lymphoblastic Institute of Hematology & Blood Diseases Hospital, China 150
Testing effectiveness (Phase 2)Looking for participantsNCT05521204What this trial is testingOlverembatinib for FGFR1-rearranged NeoplasmsWho this might be right forMyeloproliferative NeoplasmAcute Leukemia The First Affiliated Hospital of Soochow University 20
Not applicableEnrolling By InvitationNCT07383298What this trial is testingObservational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseWho this might be right forChronic Myeloid Leukemia Qian Jiang 100
Testing effectiveness (Phase 2)Looking for participantsNCT06757855What this trial is testingOlverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLWho this might be right forCML,Blast Phase Institute of Hematology & Blood Diseases Hospital, China 29
Not applicableAvailableNCT05594758What this trial is testingNamed Patient Program for Olverembatinib (HQP1351) Ascentage Pharma Group Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06754267What this trial is testingVenetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLWho this might be right forPrecursor B-Cell Acute Lymphoblastic Leukemia First Affiliated Hospital of Zhejiang University 36
Large-scale testing (Phase 3)UnknownNCT05311943What this trial is testingTreatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.Who this might be right forOlverembatinibChronic Myeloid Leukemia, Chronic PhaseTyrosine Kinase Inhibitors Shenzhen Second People's Hospital 40
Very early researchActive Not RecruitingNCT07074496What this trial is testingEfficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.Who this might be right forPhiladelphia Chromosome-Positive Acute Lymphoblastic Leukemia The First Affiliated Hospital of Soochow University 20
Early research (Phase 1)UnknownNCT05495035What this trial is testingStudy for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLWho this might be right forLymphoblastic Leukemia, Acute, ChildhoodLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveRelapsed Leukemia+1 more Institute of Hematology & Blood Diseases Hospital, China 22
Large-scale testing (Phase 3)Looking for participantsNCT06423911What this trial is testingStudy of Olverembatinib (HQP1351) in Patients With CP-CMLWho this might be right forChronic Myeloid LeukemiaCMLCML, Chronic Phase Ascentage Pharma Group Inc. 285